Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma
Kidney Cancer · 2017
DOI: 10.3233/kca-170009 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Kidney Cancer, 2017. Verfasst von Patrick G Pilié und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Approximately 16% of patients with renal cell carcinomas (RCC) present with stage IV disease at time of diagnosis. Treatment options for metastatic clear cell RCC, the most common histologic subtype, have proliferated over the past decade and include a combination of surgery and systemic therapy. The selection of systemic agent and best timing of systemic therapy in relation to nephrectomy is an area of active research.
Objective
To evaluate the evidence for perioperative systemic therapy, including presurgical and postsurgical, for metastatic RCC.
Methods
A systematic literature search using PubMed and MEDLINE databases was performed in January 2017 for articles related to perioperative systemic therapy in metastatic RCC using key word search terms. The authors screened the search results and identified selected publications by predetermined inclusion criteria and consensus. Expert opinion was obtained to assess for publications missed by search.
Results
Early phase clinical trials of antiangiogenic tyrosine kinase inhibitors prior to cytoreductive nephrectomy in select patients show that these systemic agents are safe and effective in the presurgical setting. There are no randomized data evaluating pre- or post-surgical systemic therapy in metastatic RCC.
Conclusions
Retrospective and early-phase prospective studies on the use and timing of systemic therapy in relation to cytoreductive nephrectomy in metastatic RCC show that standard of care antiangiogenic agents are safe and effective in the perioperative setting, though randomized data are still lacking. Pre-surgical immune checkpoint therapy for metastatic RCC has strong biologic rationale and holds promise. Sequential tumor sampling in neoadjuvant and presurgical trials is necessary to determine biomarkers of response and resistance.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Zitieren
APA
Pilié, P. G., & Jonasch, E. (2017). Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer. https://doi.org/10.3233/kca-170009
Vancouver
Pilié PG, Jonasch E. Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer. 2017. doi:10.3233/kca-170009
BibTeX
@article{Pili2017,
author = {Pilié, Patrick G and Jonasch, Eric},
title = {Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma},
journal = {Kidney Cancer},
year = {2017},
doi = {10.3233/kca-170009}
}
EUVIMED